Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Reference Study ID Number GP44467 www.roche.com/about_roche/roche_worldwide.htm
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal